OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
05 apr 2009 - 22:06
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus wins new drug delivery evaluation contract
Bericht
As part of the Company’s strategic focus on developing controlled release formulations for clients, OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO) announces today that it has signed a new drug delivery technology evaluation contract with a European biotech company. This is the seventh client for which OctoPlus will work on a controlled release formulation.
In October last year OctoPlus announced a strategic focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing.
Under the contract announced today, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus’ proprietary drug delivery technology. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.
Datum laatste update: 02 september 2024